Fact-checked by Grok 2 weeks ago

MCF-7

MCF-7 is an immortalized human breast cancer cell line derived from a pleural effusion of a 69-year-old Caucasian female patient with metastatic invasive ductal carcinoma, originally established in 1973 at the Michigan Cancer Foundation.^[1]^[2] This epithelial-like, adherent cell line is estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and exhibits characteristics of differentiated mammary epithelium, including the ability to process estradiol and form dome structures in culture due to fluid accumulation.^[3]^[2] Since its derivation, MCF-7 has become the most extensively studied human breast cancer cell line worldwide, featured in nearly 25,000 publications as of 2015 and serving as a foundational model for investigating hormone-responsive, ER-positive breast cancers, particularly the luminal A subtype, which represents the most common type of breast cancer.^[4]^[5] Its hormone sensitivity, particularly to estrogen, has enabled pivotal research on anti-estrogen therapies like tamoxifen, influencing clinical treatments and drug development for breast cancer patients.^[4]^[3] The line's genetic profile includes hypertriploid to hypotetraploid karyotype (modal number around 82), expression of receptors for androgen, progesterone, and glucocorticoids, and genetic instability leading to subpopulations, including potential stem cell fractions.^[2]^[1]^[3] Beyond basic characterization, MCF-7 cells are employed in diverse applications, such as studying proliferation, migration, invasion, spheroid formation for 3D modeling, angiogenesis, and interactions with mesenchymal stem cells, providing insights into tumor biology and therapeutic resistance.^[6]^[1] Despite its value, researchers note variability across subpopulations and the need for authentication due to genetic drift, emphasizing its role in pharmacogenomics and personalized medicine approaches.^[1]^[4]

Origin and History

Establishment

The MCF-7 cell line originated from a pleural effusion sample collected in June 1970 from a 69-year-old Caucasian female patient with metastatic breast adenocarcinoma.^[1] The patient, who had previously undergone a radical mastectomy, presented with widespread nodular recurrences, and the effusion was obtained during diagnostic evaluation at a medical facility affiliated with the Michigan Cancer Foundation.^[7] This fluid sample proved amenable to cell culture, unlike a concurrent attempt to establish a line from a solid chest wall nodule from the same patient, which failed to yield viable long-term growth.^[7] The isolation was conducted by Herbert D. Soule and colleagues at the Michigan Cancer Foundation (MCF) in Detroit, Michigan, marking one of the early successes in deriving a continuous human breast cancer cell line.^[8] The primary culture, designated 734B, was initiated by plating effusion-derived cells, which rapidly produced free-floating clusters alongside adherent epithelial-like cells.^[8] Serial passaging was employed to expand these populations, with initial transfers occurring at approximately 25-day intervals to allow for sufficient proliferation.^[8] This approach helped select for robustly growing cells amid the heterogeneous starting material. Establishing continuous growth presented significant challenges, as primary breast tumor samples from the era frequently exhibited limited replicative potential, senescence after a few passages, or overgrowth by non-tumor fibroblasts.^[7] To overcome these hurdles, the team utilized a specialized culture medium consisting of a 1:1 mixture of Eagle's minimal essential medium and Ham's F-12, supplemented with 10% heat-inactivated horse serum, 5% fetal calf serum (a source of growth factors), 50 ng/mL insulin (to enhance metabolic and proliferative responses), and antibiotics (penicillin and streptomycin).^[8] Insulin supplementation was particularly crucial, as it supported the hormone-responsive nature of the cells and prevented growth arrest observed in unsupplemented conditions.^[9] By 1973, after more than 90 weekly passages, the free-floating cell population had been refined into a stable, continuously propagatable line designated MCF-7, characterized by its epithelial morphology and retention of breast carcinoma features.^[8] This achievement provided the first reliably hormone-responsive model for breast cancer research, enabling subsequent studies on estrogen signaling and tumor biology.^[7]

Development and Naming

Following its initial isolation, the MCF-7 cell line underwent formal development and characterization by Dr. Herbert Soule and colleagues at the Michigan Cancer Foundation in Detroit, Michigan, during the early 1970s. The line was established from malignant cells in a pleural effusion and authenticated through karyotypic analysis, which revealed a near-triploid human chromosome complement (modal number of 82, with characteristic markers), confirming its human origin and distinguishing it from potential contaminants. This work included early biochemical assessments, such as detection of estrogen receptors, establishing MCF-7 as a hormone-responsive model. The foundational description appeared in a 1973 publication in the Journal of the National Cancer Institute, detailing its derivation, growth properties, and retention of mammary epithelial features like dome formation in culture.^[8] The nomenclature "MCF-7" reflects its origin at the Michigan Cancer Foundation (MCF) and denotes it as the seventh successful effort by Soule's team to derive a continuous breast cancer cell line from patient samples, after six prior failures. This naming convention highlighted the challenges of establishing stable human tumor lines at the time and underscored the breakthrough represented by MCF-7. Early efforts also involved standardization of culture conditions to ensure reproducibility, paving the way for its broader adoption in research.^[7] MCF-7 was deposited at the American Type Culture Collection (ATCC) in 1973 under catalog number HTB-22, enabling its initial dissemination to global laboratories and accelerating its use in cancer studies. It was later made available through the European Collection of Authenticated Cell Cultures (ECACC), further promoting standardized access. A pivotal early milestone came in 1976 with a publication in the Journal of the National Cancer Institute demonstrating the line's stability after prolonged passage; when grown in sponge culture, MCF-7 cells reexpressed the histological and antigenic patterns of the original metastatic breast carcinoma, affirming its fidelity as a model system.^[10]

Cell Line Characteristics

Morphology and Growth Properties

MCF-7 cells exhibit an epithelial-like morphology, appearing as large, polygonal cells that adhere to the substrate and form cohesive monolayers with a cobblestone appearance due to tight intercellular junctions.^[11] These monolayers often develop characteristic dome-like structures, resulting from fluid accumulation between the cell layer and the culture dish, which is a hallmark of their polarized epithelial phenotype.^[3] The growth properties of MCF-7 cells are characterized by a relatively slow proliferation rate, with a population doubling time typically ranging from 30 to 40 hours under standard conditions.^[12] Optimal seeding density for initial plating is 2-4 × 10⁴ cells/cm², and subculturing is recommended at 70-80% confluence using 0.25% trypsin-EDTA to detach the adherent cells.^[3] This adherent growth preference supports their maintenance as monolayers, though genetic instability can lead to variability in growth rates across passages.^[2] Standard culture conditions for MCF-7 cells involve Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% non-essential amino acids, and 10 μg/mL insulin to promote optimal growth and mimic physiological requirements.^[3] Cultures are maintained at 37°C in a humidified atmosphere of 5% CO₂.^[2] While primarily adherent, MCF-7 cells can form three-dimensional spheroids in low-attachment conditions, aggregating into compact structures suitable for advanced modeling.^[13]

Genetic and Molecular Features

The MCF-7 cell line exhibits a complex karyotype characterized by hypertriploid to hypotetraploid chromosome numbers, with a modal number of 82 (range 66–87), and extensive structural abnormalities including numerous translocations and derivatives across nearly all chromosomes.^[2] A highly recurrent marker is the derivative chromosome der(1;16)(q10;p10), often present in multiple copies (up to +2 to +4), resulting in gain of 1q and loss of 16q, which contributes to the line's genomic instability.^[14] This chromosomal profile reflects the aneuploidy common in breast cancer cells and has been consistently observed across cytogenetic analyses of MCF-7 sublines.^[15] At the molecular level, MCF-7 cells are defined by their estrogen receptor alpha (ERα) positivity, progesterone receptor (PR) positivity, and HER2 negativity, aligning them with the luminal A subtype of breast cancer and making them responsive to hormonal signaling.^[16] They express the WNT7B oncogene, which is implicated in Wnt/β-catenin pathway activation and tumor progression.^[2] Additionally, MCF-7 cells produce insulin-like growth factor binding proteins (IGFBPs), particularly IGFBP-2, IGFBP-4, and IGFBP-5, which modulate IGF signaling and influence cell proliferation and survival.^[2] MCF-7 cells retain the blood type O, Rh+ of the original patient and preserve differentiated mammary epithelial traits, such as the ability to process estradiol through cytoplasmic estrogen receptors, enabling estrogen-dependent growth responses.^[2] Genetic instability in MCF-7 is evident through the presence of heterogeneous subpopulations, including a stem cell-like fraction characterized by markers such as alpha-6 integrin and enhanced tumorigenicity potential, which can be isolated from mammospheres or induced under stress conditions. This variability manifests across passages, with rapid genomic alterations and divergent RNA expression profiles detectable via comparative genomic hybridization (CGH) and RNA-seq, yet often undetectable by standard short tandem repeat (STR) profiling due to its focus on bulk DNA identity rather than transcriptomic or subclonal differences.^[14] Such heterogeneity underscores the need for vigilant subline authentication in research.^[17]

Research Applications

Modeling Breast Cancer

The MCF-7 cell line serves as a key in vitro model for estrogen receptor-positive (ER+) breast cancer, particularly representing the luminal A subtype due to its expression of ER and progesterone receptor (PR), coupled with low proliferation rates and non-invasive characteristics.^[18]^[5] This profile mirrors the hormone-dependent nature of luminal A tumors, which constitute a significant portion of ER+ breast cancers and are typically responsive to endocrine therapies.^[19] Researchers utilize MCF-7 cells to recapitulate the biology of these tumors, providing insights into disease progression without relying on patient-derived samples.^[20] In studies of hormone-dependent growth, MCF-7 cells demonstrate estrogen-driven proliferation, enabling investigations into regulatory mechanisms such as cell cycle progression and apoptosis under varying hormonal conditions.^[21] To explore tumor microenvironment interactions and metastasis, MCF-7 cultures are adapted to three-dimensional (3D) formats, including spheroids and co-cultures with fibroblasts, which better simulate in vivo architecture compared to traditional two-dimensional (2D) monolayers.^[22]^[23] These 3D models reveal enhanced invasive potential and stromal influences on cancer cell behavior, facilitating the examination of extracellular matrix effects and early metastatic events.^[24]^[25] MCF-7 has significantly advanced the understanding of estrogen signaling pathways, including the molecular basis of tamoxifen responsiveness and the development of endocrine resistance.^[26] Through chronic exposure protocols, researchers have modeled resistance mechanisms, such as altered ER phosphorylation and crosstalk with growth factor receptors like EGFR/HER2, which contribute to therapy failure in ER+ tumors.^[27]^[28] These findings have elucidated adaptive changes in signaling cascades, informing strategies to overcome resistance.^[29] Over more than 50 years since its establishment in 1973, MCF-7 has been featured in tens of thousands of publications as of 2025, profoundly shaping the comprehension of ER+ tumor heterogeneity, from clonal variations to microenvironmental influences.^[4]^[18] This extensive body of work has highlighted diverse phenotypic responses within ER+ cancers, driving foundational advances in breast cancer biology. Recent applications include its integration in microfluidic organ-on-a-chip models for high-throughput simulation of tumor-stroma interactions.^[11]^[30]^[31]

Drug Development and Screening

The MCF-7 cell line, characterized by its estrogen receptor-positive (ER+) status, serves as a key model for evaluating hormone therapies in breast cancer drug development.^[32] MCF-7 cells are extensively utilized in high-throughput screening platforms to assess the efficacy of antiestrogens such as tamoxifen and fulvestrant, as well as cytotoxic agents, by measuring inhibitory concentration 50 (IC50) values through standard assays like MTT for cell viability and colony formation for proliferative potential.^[33]^[34]^[35] For instance, tamoxifen typically exhibits an IC50 of approximately 4-14 μM in MCF-7 cells via MTT assays, enabling rapid identification of compounds that disrupt ER signaling or induce apoptosis.^[33]^[36] These assays have facilitated the screening of thousands of potential therapeutics, prioritizing those with favorable potency against ER+ phenotypes.^[37] Studies employing MCF-7 cells have elucidated acquired resistance mechanisms to antiestrogens, including upregulation of epidermal growth factor receptor (EGFR) signaling and loss of ER expression following prolonged drug exposure.^[38]^[39] In tamoxifen-resistant MCF-7 derivatives, EGFR overexpression enhances survival pathways, reducing sensitivity to endocrine therapy, as demonstrated through proteomic and gene expression analyses.^[40] Similarly, fulvestrant treatment often leads to complete ER loss in resistant subpopulations, shifting dependence to alternative growth factors and informing combination strategies to overcome relapse.^[41] These findings from MCF-7 models have guided clinical trial designs for reversing resistance in ER+ breast cancers.^[38] To advance personalized medicine, MCF-7 cells are co-cultured with fibroblasts to recapitulate stromal interactions that influence drug responses, such as altered sensitivity to antiestrogens in tumor microenvironments.^[23] In 3D co-culture systems with human mammary fibroblasts (e.g., MRC-5), MCF-7 spheroids exhibit reduced efficacy of tamoxifen due to fibroblast-secreted factors promoting survival, highlighting the role of stromal crosstalk in therapeutic resistance.^[42]^[43] This approach enables patient-specific modeling, where co-cultures predict variable drug responses based on stromal composition, supporting tailored endocrine therapies.^[44] Notable outcomes from MCF-7-based research include the validation of aromatase inhibitors (e.g., letrozole) and CDK4/6 inhibitors (e.g., palbociclib) for ER+ breast cancers, demonstrating synergistic growth inhibition in combination with endocrine agents.^[45]^[46] These models confirmed that CDK4/6 inhibition arrests cell cycle progression in MCF-7 cells, enhancing aromatase inhibitor efficacy and informing approvals for advanced ER+ disease, with MCF-7 contributing to data from numerous drug-related studies.^[47]^[18]

Variants and Derivatives

Sub-lines

Sub-lines of the MCF-7 cell line are variants derived through prolonged passaging or selective pressure, such as chronic exposure to hormones or antiestrogens, resulting in distinct phenotypic and molecular properties compared to the parental line. These sub-lines maintain the core estrogen receptor-positive (ER+) status of MCF-7 but exhibit adaptations like altered hormone sensitivity and resistance mechanisms, making them valuable for studying therapeutic resistance in breast cancer.^[48] The MCF-7/S0.5 sub-line was developed by gradually adapting parental MCF-7 cells to low serum concentrations (0.5% fetal bovine serum), while maintaining dependence on estrogen for growth. This variant achieves a weekly split ratio of approximately 1:40 in 1% serum and is particularly useful as a base for generating further adaptations, such as aromatase inhibitor-resistant sub-lines that exhibit estrogen-independent growth. Unlike the baseline MCF-7 genetics, which include wild-type TP53 and ERα expression, MCF-7/S0.5 retains similar CYP19A1 (aromatase) mRNA levels to the parent line.^[48]^[49] Tamoxifen-resistant sub-lines, such as MCF-7/TAMR (also denoted MCF-7/TAMR-1), are generated by long-term exposure of MCF-7 cells to 4-hydroxytamoxifen, resulting in stable resistance to this selective estrogen receptor modulator (SERM). These variants exhibit upregulated expression of ATP-binding cassette (ABC) transporters, including ABCG2 and MRP2, which contribute to drug efflux and multidrug resistance phenotypes. For instance, MCF-7/TAMR cells proliferate in the presence of micromolar concentrations of tamoxifen that inhibit the parental line, accompanied by altered estrogen-regulated gene profiles.^[50]^[51] Another notable variant is MCF-7/LCC2, derived from long-term estrogen deprivation (LTED) of MCF-7 cells, modeling resistance to aromatase inhibitors or ovarian suppression therapies. This sub-line displays hypersensitivity to low estrogen levels, faster growth rates in estrogen-deprived media (approximately 1.5-2 times higher than parental MCF-7), and elevated expression of markers like epidermal growth factor receptor (EGFR) while retaining ERα positivity. MCF-7/LCC2 cells are resistant to tamoxifen but sensitive to pure antiestrogens like fulvestrant, highlighting adaptive signaling shifts in therapy-induced resistance.^[52]^[53] Authentication of MCF-7 sub-lines poses challenges, as they typically retain the parental short tandem repeat (STR) profile for species and identity verification but show significant divergence in RNA expression and genomic modifications. Studies of multiple MCF-7 sub-lines, including those resistant to antiestrogens, reveal rapid changes in gene expression profiles—up to 20-30% differential expression in key pathways—necessitating sub-line-specific validation through RNA sequencing or functional assays beyond standard STR testing to ensure reproducibility.^[54]^[55]

Modified Lines

Modified lines of MCF-7 cells involve intentional genetic engineering to introduce specific alterations, enabling precise interrogation of molecular mechanisms in breast cancer. These derivatives are created using techniques such as CRISPR/Cas9 for targeted knockouts or knock-ins, viral transduction for stable transfections, and RNA interference for transient knockdowns, allowing researchers to isolate the effects of individual genes or pathways without the confounding variables of the parental line.^[56] CRISPR/Cas9-mediated knockouts have been widely employed to generate MCF-7 variants lacking key genes, facilitating studies on hormone signaling and oncogene dependencies. For instance, estrogen receptor alpha (ERα) knockout MCF-7 lines have been developed to investigate estrogen-independent growth and endocrine therapy resistance, revealing that ERα loss shifts cellular proliferation toward alternative pathways like MAPK signaling.^[57] Similarly, HER2-overexpressing MCF-7 derivatives, achieved via CRISPR activation or stable integration, model luminal-to-HER2-enriched subtype conversion, demonstrating enhanced invasion and altered sensitivity to HER2-targeted inhibitors like trastuzumab.^[58] These knockouts provide high-fidelity tools for dissecting gene-specific contributions to tumor progression. Transfected MCF-7 lines often feature stable overexpression of anti-apoptotic or reporter genes to probe survival mechanisms and enable non-invasive tracking. Overexpression of BCL-2, an anti-apoptotic oncogene, in MCF-7 cells via lentiviral transduction has been used to study resistance to chemotherapy-induced apoptosis, showing that elevated BCL-2 levels suppress cytochrome c release and caspase activation, thereby promoting cell survival under stress.^[59] Luciferase-tagged MCF-7 variants, such as those expressing firefly luciferase under CMV control, support in vivo bioluminescence imaging in xenograft models, allowing real-time monitoring of tumor growth and metastasis with high signal-to-background ratios.^[60] Other modifications include siRNA-based knockdowns for pathway analysis and adaptations into 3D organoid formats with integrated mutations. siRNA knockdown of PI3K or AKT in MCF-7 cells inhibits the PI3K/AKT pathway, reducing phosphorylation of downstream targets like 4E-BP1 and sensitizing cells to apoptosis inducers, which aids in evaluating pathway-targeted therapies.^[61] Additionally, MCF-7-derived 3D organoids incorporating lentiviral mutations, such as in PTEN or TP53, recapitulate tumor architecture and heterogeneity, enabling studies on matrix interactions and drug penetration in a physiologically relevant context.^[62] These modified lines enhance precision research by isolating the roles of specific mutations in processes like metastasis and immunotherapy response; for example, HER2-modified MCF-7 variants have been used to assess CAR-T cell efficacy against low-HER2 tumors, revealing improved cytotoxicity when combined with checkpoint inhibitors.^[63] They also support advanced modeling of drug resistance mechanisms, complementing broader screening efforts.^[64]

References

[1]
Cellosaurus cell line MCF-7 (CVCL_0031)
Identification of cancer cell-line origins using fluorescence image-based phenomic screening. PLoS ONE 7:e32096.1-e32096.8(2012). PubMed=22414580; DOI ...
[2]
MCF7 - HTB-22 - ATCC
The MCF7 line retains several characteristics of differentiated mammary epithelium including ability to process estradiol via cytoplasmic estrogen receptors ...
[3]
MCF7 - ECACC cell line profiles - Culture Collections
MCF7 was derived from the pleural effusion from a 69 year old female suffering from a breast adenocarcinoma1. It was named after the Michigan Cancer Foundation ...
[4]
changing the course of breast cancer research and care for 45 years
Mar 31, 2015 · MCF-7 is the most studied human breast cancer cell line in the world, and results from this cell line have had a fundamental impact upon breast ...
[5]
MCF cell lines that transformed breast cancer research
The MCF-7 cell line is used by researchers throughout the world as a model of ER positive breast cancer and for characterization of antiestrogen response and ...<|control11|><|separator|>
[6]
The Story of MCF-7 Breast Cancer Cell Line: 40 years of ... - PubMed
The current paper provides a broad description of the MCF-7 cell line, including the molecular profile, proliferation, migration, invasion, spheroid formation, ...
[7]
MCF-7 Cells—Changing the Course of Breast Cancer Research and ...
Mar 31, 2015 · MCF-7 is the most studied human breast cancer cell line in the world, and results from this cell line have had a fundamental impact upon breast ...
[8]
A Human Cell Line From a Pleural Effusion Derived From ... - PubMed
A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409-16. doi: 10.1093/jnci/51.5.1409.Missing: isolation Herbert 1970 Michigan Foundation
[9]
Effects of serum and insulin on the sensitivity of the human breast ...
Insulin changes the sensitivity of MCF-7 cells to both estrogen and antiestrogens. Cells growing in media containing insulin are less sensitive to inhibition.
[10]
Breast Cancer MCF-7 Cells Acquire Heterogeneity during ... - NIH
Nov 10, 2022 · MCF-7 cells in culture display a large epithelial cell shape and an attachment growth behavior with intercellular contact to form cobblestone- ...
[11]
Doubling time of breast adenocarcinoma cell line MCF-7
Doubling time of breast adenocarcinoma cell line MCF-7 ; The population doubling time Td of the MCF-7 cells during exponential growth was approximately 35 h.Missing: standard | Show results with:standard
[12]
MCF-7 Human Breast Cancer Cells Form Differentiated Microtissues ...
Aug 12, 2015 · When grown in 3D using scaffold-free agarose hydrogels, MCF-7 human breast cancer cells self-organize to form directionally-oriented microtissues that contain ...Missing: initial continuous
[13]
EGFR-dependent aerotaxis is a common trait of breast tumour cells ...
Hypertriploid to hypotetraploid (modal number 80 ~ 84). Very numerous structural abnormalities. Three normal X chromosomes in most cells. -. -. +. Lu.
[14]
Genetic variability in MCF-7 sublines: evidence of rapid genomic ...
This cell line has been originally established in 1973 at the Michigan Cancer Foundation from a pleural effusion taken from a woman with metastatic breast ...
[15]
Differences and homologies of chromosomal alterations within and ...
Jan 23, 2014 · The cytogenetic analysis performed on 26 metaphases of MCF7 cells demonstrated a modal number hypertriploid to hypotetraploid (4n+/-) (76 to 88 ...Missing: 82 | Show results with:82
[16]
Table 1 Molecular classification of breast carcinoma
ER+, PR+/-, HER2-. Ki67 low, endocrine responsive, often chemotherapy responsive. MCF-7, T47D, SUM185. Luminal B. ER+, PR+/-, HER2+. Ki67 high, usually ...
[17]
Selecting suitable reference genes for qPCR normalization
Sep 25, 2020 · Established in 1970 by researcher Herbert D. Soule at the Michigan Cancer Foundation, the cell line is derived from the pleural effusion and ...
[18]
The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience ...
MCF-7 cells exhibit features of differentiated mammary epithelium: they are positive for epithelial markers, such as E-cadherin, β-catenin and cytokeratin 18 ( ...
[19]
Establishment of a normal-derived estrogen receptor-positive cell ...
In a breast fibroblast co-culture model we further show that whereas MCF7 proliferate concurrently with ER expression, iHBECERpos form correctly polarized acini ...
[20]
Choosing the right cell line for breast cancer research
Aug 12, 2011 · The popularity of MCF-7 is largely due to its exquisite hormone sensitivity through expression of oestrogen receptor (ER), making it an ideal ...
[21]
MCF-7 Cells - Cytion
MCF7 cells, a widely used research model in human breast cancer research, are utilized extensively as an in vitro model for hormone-dependent breast cancer.Missing: formation | Show results with:formation<|control11|><|separator|>
[22]
MCF-7 Cells as a Three-Dimensional Model for the Study of Human ...
The present work describes a method that permits luminal formation in breast adenocarcinoma cell (MCF-7)-derived spheroids in a 3D environment.
[23]
Advanced co-culture 3D breast cancer model for investigation of ...
Dec 4, 2020 · We optimized the protocol for the formation of co-culture spheroids, consisting of the luminal breast cancer MCF-7 cells and MRC-5 fibroblasts.
[24]
Studying breast cancer lung metastasis using a multi-compartment ...
To model the primary tumor microenvironment, breast cancer cells (MCF7) and cancer-associated fibroblasts (CAFs) were co-cultured within the tumor compartment ...Missing: MCF- | Show results with:MCF-
[25]
A Journey from 2D to 3D Cancer Models and Nanoscale Therapies
Breast cancer MCF-7 cells cultured in 3D gels formed spheroid clusters, similar to in vivo conditions, unlike the flat shape seen in 2D cultures. They ...
[26]
Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells ... - NIH
Jun 2, 2017 · Tamoxifen, a selective estrogen receptor modulator (SERM), has been shown to increase the 15-year survival rate of hormone receptor-positive ...
[27]
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor ...
Acquired tamoxifen resistance in MCF-7 tumors is associated with increased EGFR/HER2 expression. First, we examined the levels of EGFR and HER2 in tumors that ...
[28]
Induced Tamoxifen Resistance is Mediated by Increased ... - Nature
Oct 2, 2019 · MCF-7 cells chronically treated with tamoxifen eventually developed resistance against the drug. This resistance was confirmed by cell ...
[29]
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells ...
Our data demonstrate that the adaptive changes in the proteome of tamoxifen resistant breast cancer cells are characterized by down-regulated ER signaling, ...
[30]
The complex nature of heterogeneity and its roles in breast cancer ...
In MCF7 cells, intracellular transcriptomic heterogeneity was dominated by cell cycle states but a rare subpopulation of MCF7 cells showed a unique ...
[31]
MCF-7aro/ERE, a Novel Cell Line for Rapid Screening of Aromatase ...
We have previously generated a breast cancer cell line, MCF-7aro, which over-expresses aromatase and is also ER-positive. Recently, this MCF-7aro cell line ...
[32]
Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway ...
Feb 21, 2021 · The IC50 of tamoxifen in MCF-7 and MCF-7/TAM is 13.57 μM and ... a MTT assay showed that the cell viability of MCF-7 cells which was ...
[33]
Tamoxifen-resistant breast cancer cells are resistant to DNA ... - Nature
Apr 23, 2018 · We report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy.
[34]
Antiproliferative and apoptotic activity of glycyrrhizinic acid in MCF-7 ...
Colony formation assay. For this assay, MCF-7 cells were harvested and then counted using a haemocytometer. The cells were seeded at 200 cells/well, then ...Missing: screening | Show results with:screening
[35]
Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the ...
Aug 2, 2006 · The IC50 for tamoxifen in MCF-7 and Ac1 cells was 4.2 ± 0.8 and 5.3 ± 0.5 μmol/L, respectively. The results showed that both cell lines are ...
[36]
Antiestrogen-resistant subclones of MCF-7 human breast cancer ...
Aug 25, 2009 · We thank Ana Soto and Carlos Sonnenschein (Tufts University) for MCF-7 BUS cell culture, Ai Muto (Kyoto University) for bioinformatics, and ...
[37]
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance ...
Feb 3, 2015 · Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression. Xia Zhang ...
[38]
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells ...
Mar 14, 2012 · On the other hand, complete loss of ER expression has occurred when MCF-7 cells became resistant to the pure antiestrogen, fulvestrant [43–45].
[39]
International Journal of Oncology - Spandidos Publications
Jan 26, 2015 · EGFR level was low in MCF-7 cells and also in exemestane-resistant cell lines, whereas increased level of EGFR was seen in all four letrozole- ...Missing: throughput | Show results with:throughput
[40]
Mechanisms of Tumor Regression and Resistance to Estrogen ...
This loss of ER is in distinct contrast to acquired resistance to estrogen deprivation in the parental MCF7 cells, which develop very high levels of ER and ...
[41]
Co-culture of Primary Human Mammary Fibroblasts and MCF-7 ...
In this study, a technique that allows for culturing MCF-7 epithelial breast tumor cells and healthy primary human mammary fibroblasts together in one ...
[42]
Mimicking 3D breast tumor-stromal interactions to screen novel ...
Nov 1, 2023 · We have established an in vitro 3D heterotypic spheroid model including MCF-7 breast tumor cells, human mammary fibroblasts and human macrophages.
[43]
Personalized in vitro Cancer Models to Predict Therapeutic Response
We will review traditional and emerging in vitro models for personalized medicine, focusing on the technologies, microenvironmental components, and readouts ...
[44]
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase ...
Sep 24, 2022 · Aromatase inhibitors (AI) have proven clinical efficacy both in the adjuvant and advanced settings in estrogen receptor-positive (ER+) breast ...
[45]
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in ...
We assessed the steadiness of cell-cycle arrest induced by CDK4/6 inhibition in the ER-positive breast cancer cell lines MCF-7 and T47D. Palbociclib ...
[46]
Co-targeting CDK4/6 and AKT with endocrine therapy prevents ...
Aug 25, 2021 · We show that triple inhibition with fulvestrant, CDK4/6i and AKT inhibitor (AKTi) durably impairs growth of breast cancer cells, prevents progression and ...
[47]
MCM3 upregulation confers endocrine resistance in breast cancer ...
Jan 4, 2021 · The MCF-7 cells were gradually adapted to grow in low serum concentration and the tamoxifen-sensitive subline MCF-7/S0.5 was used to establish ...<|control11|><|separator|>
[48]
New cell culture model for aromatase inhibitor-resistant breast ... - NIH
The parental cell line for the AI-resistant cell lines was MCF-7 subline 0.5 (MCF-7/S0.5), which originates from MCF-7 cells from the Human Cell Culture ...
[49]
CXCR4 activation maintains a stem cell population in tamoxifen ...
May 29, 2012 · ABCG2 is overexpressed in tamoxifen-resistant MCF7 breast cancer cells. To identify the molecular mechanisms of resistance to tamoxifen in MCF7 ...
[50]
Induction of multidrug resistance associated protein 2 in tamoxifen ...
Jun 1, 2007 · The inhibition of PI3-kinase significantly reduced both the PXR activity and MRP2 expression in TAMR-MCF-7 cells. Overall, MRP2 induction plays ...
[51]
Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in ...
Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9. by. Min Jiang.
[52]
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth ...
MCF-7/LCC2 is a selective ER-positive, TAM-resistant cell line (Brunner et al., 1993; Lilling et al., 2000). The specific ER ligand 17β-estradiol (E2) ...
[53]
Genetic variability in MCF-7 sublines: evidence of rapid genomic ...
Expression profiles of 8 MCF-7 sublines were analyzed along with those of 19 unrelated breast cancer cell lines using home made cDNA arrays comprising 720 genes ...Missing: authentication STR
[54]
Genetic variability in a frozen batch of MCF-7 cells invisible in ...
Jul 26, 2016 · STR profiling just fulfills the purpose of authentication testing, which is to detect significant cross-contamination and cell line ...
[55]
Estrogen-regulated feedback loop limits the efficacy of ... - PNAS
In this study, we conducted genome-wide CRISPR knockout screens on two ER+ breast cancer cell lines to identify key mediators of endocrine resistance. Based on ...
[56]
HER2 expression as a potential marker for response to therapy ...
Apr 4, 2006 · The MCF7 breast cancer cell line was transfected with a pcDNA 3.1 construct encoding human HER2 that was derived from a retroviral construct ( ...
[57]
Downregulation of autophagy by Bcl-2 promotes MCF7 breast ...
Oct 1, 2010 · We show that Bcl-2-mediated antagonism of autophagy has a critical role in enhancing the tumorigenic properties of MCF7 breast cancer cells independent of its ...
[58]
MCF7-Luc2 - HTB-22-LUC2 - ATCC
MCF7-Luc2 is an epithelial-like cell of a 69 –year-old, White, female with mammary gland adenocarcinoma. The cell line expresses luciferase gene luc2.
[59]
Activation of the PI3 kinase pathway by retinoic acid mediates ...
Apr 15, 2009 · RA also induced rapid activation of Akt in MCF-7 cells. Treatment with an Akt inhibitor or Akt knockdown with siRNA reduced NIS expression.
[60]
Organoids as Reliable Breast Cancer Study Models: An Update
MCF-7 cells have been widely utilized for the purpose of breast cancer ... 3D organoid cultures [73]. These organoids were transduced via lentiviral ...Missing: derivatives | Show results with:derivatives
[61]
Сytotoxic effect of CAR-T cells against modified MCF-7 breast ...
To be able to treat patients with metastatic HER2-negative breast cancer, the NCT02792114 study seeks to establish an effective dose of mesothelin-CAR-T cells.
[62]
PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 ...
Combination of MTX chemotherapy with BCRP siRNA and PI3K/Akt inhibition can overcome MDR in breast cancer cells.